Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Aligos Therapeutics (ALGS) Tax Provisions (2021 - 2025)

Aligos Therapeutics filings provide 5 years of Tax Provisions readings, the most recent being $30000.0 for Q4 2025.

  • On a quarterly basis, Tax Provisions rose 11.11% to $30000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $314000.0, a 5.14% decrease, with the full-year FY2025 number at $314000.0, down 5.14% from a year prior.
  • Tax Provisions hit $30000.0 in Q4 2025 for Aligos Therapeutics, down from $56000.0 in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $757000.0 in Q2 2023 to a low of -$58000.0 in Q4 2021.
  • Median Tax Provisions over the past 5 years was $44000.0 (2021), compared with a mean of $84350.0.
  • The widest YoY moves for Tax Provisions: up 1510.64% in 2023, down 161.22% in 2023.
  • Aligos Therapeutics' Tax Provisions stood at -$58000.0 in 2021, then soared by 184.48% to $49000.0 in 2022, then plummeted by 161.22% to -$30000.0 in 2023, then skyrocketed by 190.0% to $27000.0 in 2024, then increased by 11.11% to $30000.0 in 2025.
  • The last three reported values for Tax Provisions were $30000.0 (Q4 2025), $56000.0 (Q3 2025), and $185000.0 (Q2 2025) per Business Quant data.